Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer Keiser

Showing results (11-20 of 446) with videos related to

Pageof 45
Sort By:
Current Opinion in Infectious Diseases|November 3, 2007
Artemisinins and synthetic trioxolanes in the treatment of helminth infectionsJennifer Keiser, Jürg Utzinger
Parasitology International|April 27, 2010
Effect of artemether, artesunate, OZ78, praziquantel, and tribendimidine alone or in combination chemotherapy on the tegument of Clonorchis sinensisJennifer Keiser, Mireille Vargas
The Lancet. Global Health|August 9, 2014
Research and development for neglected diseases: more is still needed, and fasterJürg Utzinger, Jennifer Keiser
The Lancet. Infectious Diseases|August 3, 2025
Emodepside for strongyloidiasis: insights from parasite genetics - Authors' replyLyndsay Taylor, Jennifer Keiser
Advances in Parasitology|July 15, 2010
The drugs we have and the drugs we need against major helminth infectionsJennifer Keiser, Jürg Utzinger
Parasites & Vectors|December 24, 2021
Assessment of FDA-approved drugs against Strongyloides ratti in vitro and in vivo to identify potentially active drugs against strongyloidiasisJennifer Keiser, Cécile Häberli
Current Opinion in Pharmacology|August 5, 2018
Acting beyond 2020: better characterization of praziquantel and promising antischistosomal leadsGordana Panic, Jennifer Keiser
Emerging Infectious Diseases|December 2, 2005
Emerging foodborne trematodiasisJennifer Keiser, Jürg Utzinger
Expert Opinion on Drug Discovery|March 16, 2013
Advances in the discovery and development of trematocidal drugsJennifer Keiser, Jürg Utzinger
Parasites & Vectors|August 13, 2015
Repurposing of anticancer drugs: in vitro and in vivo activities against Schistosoma mansoniNoemi Cowan, Jennifer Keiser
Pageof 45

Showing results (11-20 of 446) with videos related to

Sort By:
Pageof 45
Current Opinion in Infectious Diseases|November 3, 2007
Artemisinins and synthetic trioxolanes in the treatment of helminth infectionsJennifer Keiser, Jürg Utzinger
Parasitology International|April 27, 2010
Effect of artemether, artesunate, OZ78, praziquantel, and tribendimidine alone or in combination chemotherapy on the tegument of Clonorchis sinensisJennifer Keiser, Mireille Vargas
The Lancet. Global Health|August 9, 2014
Research and development for neglected diseases: more is still needed, and fasterJürg Utzinger, Jennifer Keiser
The Lancet. Infectious Diseases|August 3, 2025
Emodepside for strongyloidiasis: insights from parasite genetics - Authors' replyLyndsay Taylor, Jennifer Keiser
Advances in Parasitology|July 15, 2010
The drugs we have and the drugs we need against major helminth infectionsJennifer Keiser, Jürg Utzinger
Parasites & Vectors|December 24, 2021
Assessment of FDA-approved drugs against Strongyloides ratti in vitro and in vivo to identify potentially active drugs against strongyloidiasisJennifer Keiser, Cécile Häberli
Current Opinion in Pharmacology|August 5, 2018
Acting beyond 2020: better characterization of praziquantel and promising antischistosomal leadsGordana Panic, Jennifer Keiser
Emerging Infectious Diseases|December 2, 2005
Emerging foodborne trematodiasisJennifer Keiser, Jürg Utzinger
Expert Opinion on Drug Discovery|March 16, 2013
Advances in the discovery and development of trematocidal drugsJennifer Keiser, Jürg Utzinger
Parasites & Vectors|August 13, 2015
Repurposing of anticancer drugs: in vitro and in vivo activities against Schistosoma mansoniNoemi Cowan, Jennifer Keiser
Pageof 45